IL2 and neoplasm: These events inhibited mitogen-induced lymphocyte proliferation and the production of interleukin-2 (31, 32), thus hindering anti-tumor immunity and upregulating vascular endothelial growth factor, which accelerated tumor angiogenesis (33, 34).